Last reviewed · How we verify
NCT05654415
Melatonin vs Sleep Deprivation for Nap EEG
NA trial testing Melatonin in Epilepsy in 30 participants. Status unknown.
31 December 2022
Quick facts
| Lead sponsor | IRCCS National Neurological Institute "C. Mondino" Foundation |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 September 2021 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Melatonin (MELATONIN) — full drug profile →
- Deprivation
Conditions studied
- Epilepsy — all drugs for Epilepsy →
Sponsor
IRCCS National Neurological Institute "C. Mondino" Foundation
Who can join
Adults 4 to 10, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In the pediatric population, electroencephalographic (EEG) recordings are frequently performed in sleep, as it reduces the amount of artifacts and might activate epileptiform discharges. To date, no agreed-upon guidelines are available for hypno-induction for EEG recordings . Among the strategies used, the most commonly used are sleep deprivation, either total or partial, and the use of melatonin, alone or in combination. The investigators proposed a study aiming at evaluating the efficacy of a melatonin-based solution for sleep induction during EEG video recording VS sleep deprivation. In a randomized, crossover study, 30 pediatric patients (aged 4-10 years) will be subjected to two EEG recordings: in one they will receive the melatonin solution (5 mg), in the other they undergo only partial sleep deprivation (about 50% of physiological sleep). The primary endpoint of the study is represented by the time to fall asleep, secondary objectives are represented by frequency of epileptiform discharges, presence/absence of epileptic seizures, In addition, the levels of 6-sulfatoxymelatonina, the primary metabolite of melatonin in saliva and urine, will be determined with a validated LC-MS method.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Melatonin versus Sleep Deprivation for Sleep Induction in Nap Electroencephalography: Protocol for a Prospective Randomized Crossover Trial in Children and Young Adults with Epilepsy.
Varesio C, Franco V, Pasca L, Celario M, et al · · 2023 · cited 2× · PMID 36984823 · DOI 10.3390/metabo13030383 -
A prospective randomized crossover trial investigating melatonin versus sleep deprivation for sleep induction in nap electroencephalography.
De Giorgis V, Varesio C, Celario M, Quaranta CA, et al · · 2026 · cited 1× · PMID 41208640 · DOI 10.1002/epi4.70169 -
Mitochondria and oxidative stress in epilepsy: advances in antioxidant therapy.
Ji D, Mylvaganam S, Ravi Chander P, Tarnopolsky M, et al · · 2024 · cited 1× · PMID 40177125 · DOI 10.3389/fphar.2024.1505867
Verify or expand the search:
- PubMed search for NCT05654415
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Melatonin
Trials testing the same drug.
- NCT07221968 — Melatonin for the Treatment of DEE-SWAS · Phase 2 · not yet recruiting
- NCT07503600 — The Effect of Adjunctive Melatonin With Colistin in Patients With Multidrug-Resistant Gram-Negative Bacterial Infections · Phase 3 · not yet recruiting
- NCT07375342 — Melatonin for Post Tonsillectomy Emergence Agitation in Pediatric · NA · enrolling by invitation
- NCT07305350 — EFFICACY OF MELATONIN IN MANAGEMENT OF HYPOXIC ISCHEMIC ENCEPHALOPATHY (HIE) IN NEONATES · Phase 2 · active not recruiting
- NCT07096635 — Oral Melatonin With Intra Articular Analgesia on Pain After Arthroscopic Anterior Cruciate Ligament Reconstruction · NA · not yet recruiting
Other recruiting trials for Epilepsy
Currently open trials in the same condition.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
- NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
- NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
- NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting
Other IRCCS National Neurological Institute "C. Mondino" Foundation trials
Trials by the same sponsor.
- NCT06820411 — A Pilot Study to Assess Optimal Prevention and Outcome Improvement in Young Ischemic Stroke · NA · active not recruiting
- NCT06983119 — Case-Finding for Neurocognitive Disorders in Pavia · NA · recruiting
- NCT06453863 — Effects of Biofeedback Footwear in Parkinson's Disease: Assessment of Functional Motor Abilities and Locomotion · NA · not yet recruiting
- NCT06715436 — Multiple Sclerosis and the Effects of Ketogenic Diet Therapy · NA · recruiting
- NCT07442916 — Non-Invasive Brain Stimulation as Add-on Treatment in Chronic Migraine With Medication Overuse · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05654415 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IRCCS National Neurological Institute "C. Mondino" Foundation
- Last refreshed: 16 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05654415.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing